Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study
Open Access
- 14 March 2011
- journal article
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 14 (08), 1017-1027
- https://doi.org/10.1017/s146114571100040x
Abstract
Clinical trials today are conducted in multiple countries to enhance patient recruitment and improve efficiency of trials. However, the demographic aThis publication has 13 references indexed in Scilit:
- A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007)European Neuropsychopharmacology, 2010
- Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced studyJournal of Psychopharmacology, 2008
- Increasing rates of placebo response over time in mania studies.The Journal of Clinical Psychiatry, 2008
- Dosing in Obesity: A Simple Solution to a Big ProblemCancer Cell, 2007
- A systematic review of placebo response in studies of bipolar mania.The Journal of Clinical Psychiatry, 2007
- Risperidone in the treatment of acute maniaThe British Journal of Psychiatry, 2005
- Placebo Control Groups in Trials of Major Depressive Disorder Among Older PatientsJournal of Clinical Psychopharmacology, 2005
- The Use of Placebo in Clinical Trials on Bipolar Disorder: A New Approach for an Old DebatePsychotherapy and Psychosomatics, 2004
- Clinical trials in Russia and Eastern Europe: recruitment and quality.International journal of clinical pharmacology and therapeutics, 2003
- Chlorpromazine Equivalent Doses for the Newer Atypical AntipsychoticsThe Journal of Clinical Psychiatry, 2003